Equal sensitivity of early and late scans after injection of FDG for the detection of Alzheimer pattern: An analysis of 3D PET data from J-ADNI, a multi-center study

Annals of Nuclear Medicine

Volumn 27, Issue 5, 2013, Pages 452-459

  Takahashi, Ryuichi ^a,b   Ishii, Kazunari ^a,c   Senda, Michio ^a,d   Ito, Kengo ^a,e   Ishii, Kenji ^a,f   Kato, Takashi ^a,e   Makishi, Yoko ^a,d   Nishio, Tomoyuki ^a,d   Ikari, Yasuhiko ^a,d   Iwatsubo, Takeshi ^g  

^a J ADNI PET Core   (Japan)

^b Rehabilitation Nishi Harima Hospital   (Japan)

^c KINKI UNIVERSITY   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

3D; Accumulation time; Alzheimer's disease; PET; Voxel

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; HEMISPHERE; HUMAN; JAPANESE; MALE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINUS VENOSUS;

AGED; ALZHEIMER DISEASE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; INJECTIONS, INTRAVENOUS; JAPAN; MALE; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84879013694     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0704-x     Document Type: Article

References (15)

1. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-7.
2. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
3. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol. 1979;6:371-88.
4. Lucignani G, Schmidt KC, Moresco RM, Striano G, Colombo F, Sokoloff L, et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. J Nucl Med. 1993;34:360-9.
5. Schmidt KC, Lucignani G, Sokoloff L. Fluorine-18-fluorodeoxyglucose PET to determine regional cerebral glucose utilization: a re-examination. J Nucl Med. 1996;37:394-9.
6. Sakamoto S, Ishii K, Hosaka K, Mori T, Sasaki M, Mori E. Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-[fluorine 18]-fluoro-2-deoxy-d-glucose. AJNR Am J Neuroradiol. 2005;26:843-7.
7. Chen WP, Matsunari I, Noda A, Yanase D, Yajima K, Takeda N, et al. Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med. 2005;46:1633-41.
8. Arai H, Okamura N, Furukawa K, Kudo Y. Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development. Tohoku J Exp Med. 2010;221:87-95.
9. Ikari Y, Nishio T, Makishi Y, Miya Y, Ito K, Koeppe RA, et al. Head motion evaluation and correction for PET scans with 18F-FDG in the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. Ann Nucl Med. 2012;26:535-44.
10. Cross DJ, Minoshima S, Nishimura S, Noda A, Tsukada H, Kuhl DE. Three-dimensional stereotactic surface projection analysis of macaque brain PET: development and initial applications. J Nucl Med. 2000;41:1879-87.
11. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport. 2001;12:851-5.
12. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-16.
13. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-13.
14. Fair DA, Schlaggar BL, Cohen AL, Miezin FM, Dosenbach NU, Wenger KK, et al. A method for using blocked and event-related fMRI data to study "resting state" functional connectivity. Neuroimage. 2007;35:396-405.
15. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676-82.